Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Phase 2

Completed

• Conditions: Advanced Hepatocellular Carcinoma
• Interventions: Drug: ABT-869

• Registration Number: NCT00517920
• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Detailed Description

An Open-label, Phase 2 study of efficacy and tolerability of ABT-869 in advanced hepatocellular carcinoma (HCC)

Study Timeline

• Study First Submitted: 2007-08-16
• Study First Submitted QC: 2007-08-16
• Study First Posted: 2007-08-17
• Study Start: 2007-09
• Primary Completion: 2011-06
• Study Completion: 2012-06
• Disposition First Submitted: 2012-06-29
• Disposition First Submitted QC: 2012-06-29
• Disposition First Posted: 2012-07-03
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-02
• Last Update Posted: 2013-01-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ABT-869	ABT-869	-

Primary Outcome Measures

Name	Time	Method
Progression-Free Rate	Week 16
Objective Response Rate	Week 16

Trial Locations

Locations (6)

Site Reference ID/Investigator# 5235; 🇸🇬 Singapore, Singapore

Site Reference ID/Investigator# 5611; 🇸🇬 Singapore, Singapore

Site Reference ID/Investigator# 5837; 🇨🇦 Vancouver, Canada

Site Reference ID/Investigator# 7169; 🇨🇦 Toronto, Canada

Site Reference ID/Investigator# 7726; 🇺🇸 Philadelphia, Pennsylvania, United States

Site Reference ID/Investigator# 6265; 🇨🇳 Taipei, Taiwan